Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;43(Suppl 2):605-614.
doi: 10.1007/s10072-020-04998-y. Epub 2021 Jan 16.

Update on therapy of chronic immune-mediated neuropathies

Chiara Briani  1 , Dario Cocito  2 , Marta Campagnolo  3 , Pietro Emiliano Doneddu  4 , Eduardo Nobile-Orazio  4   5
Affiliations
Review

Update on therapy of chronic immune-mediated neuropathies

Chiara Briani et al. Neurol Sci. 2022 Dec.

Abstract

Chronic immune-mediated neuropathies, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), neuropathies associated with monoclonal gammopathy, and multifocal motor neuropathy (MMN), are a group of disorders deemed to be caused by an immune response against peripheral nerve antigens. Several immune therapies have been reported to be variably effective in these neuropathies including steroids, plasma exchange, and high-dose intravenous (IVIg) or subcutaneous (SCIg) immunoglobulins. These therapies are however far from being invariably effective and may be associated with a number of side effects leading to the use of immunosuppressive agents whose efficacy has not been so far confirmed in randomized trials. More recently, new biological agents, such as rituximab, have proved to be effective in patients with neuropathy associated with IgM monoclonal gammopathy and are currently tested in CIDP.

Keywords: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); Immune-mediated neuropathies; Intravenous or subcutaneous immunoglobulins; Multifocal motor neuropathy (MMN); Neuropathies; Paraproteinemic; Rituximab.

PubMed Disclaimer

References

    1. Lehmann HC, Broke N, Kuwabara S (2019) Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 90:981–987
    1. Oaklander AL, Lunn MP, Hughes RA et al (2017) Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 1:CD010369
    1. Hughes RA, Mehndiratta MM, Rajabally YA (2017) Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 11:CD002062
    1. Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15:1–9
    1. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn P, ICE Study Group (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136–144

MeSH terms

Substances

LinkOut - more resources